Je was op zoek naar: olanzapinbehandlede (Noors - Engels)

den økte mortaliteten blant olanzapinbehandlede pasienter sammenlignet med placebobehandlede var imidlertid uavhengig av disse risikofaktorene.
however, the incidence of death was higher in olanzapine- treated than in placebo-treated patients independent of these risk factors.

uønskede lipidendringer er sett hos olanzapinbehandlede pasienter i placebokontrollerte studier (se pkt.4.8).
undesirable alterations in lipids have been observed in olanzapine-treated patients in placebo- controlled clinical trials (see section 4.8).

i en annen 26-ukers, langtids kontrollert studie var hyppigheten av eps 14,8 % for aripiprazolbehandlede pasienter og 15,1 % for olanzapinbehandlede pasienter.
in another long-term 26-week controlled trial, the incidence of eps was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.

i placebokontrollerte kliniske studier (6-12 ukers varighet) hos eldre pasienter (gjennomsnittsalder 78 år) med demensrelatert psykose og/eller adferdsforstyrrelser var det en dobling i mortalitet blant olanzapinbehandlede pasienter sammenlignet med placebobehandlede pasienter (henholdsvis 3,5 % met 1,5 %).
in placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine-treated patients compared to patients treated with placebo (3.5 % versus 1.5 %, respectively).